Skip to main content
Premium Trial:

Request an Annual Quote

N-of-One, GenomiCare Partner on Interpreting NGS Tests in China

NEW YORK (GenomeWeb) – N-of-One today announced that it has signed an agreement to provide clinical interpretations for GenomiCare's next-generation sequencing-based oncology panels in China.

N-of-One provides therapeutic strategies relevant to specific cancer cases based on genomic data. Shanghai-based GenomiCare uses NGS to identify mutations and copy number variations across a tumor's exome.

"[T]he combination of this rich clinical knowledge, along with GenomiCare's multiple avenues to connect patients with China-focused treatment solutions, will significantly benefit Chinese cancer patients," GenomiCare President Qiang Xu said in a statement.

Financial and other details of the agreement were not disclosed.

Last month, N-of-One signed an agreement to provide clinical interpretation for CompanionDx. In May, the firm signed a copy number variation interpretation deal with Affymetrix.